<?xml version="1.0" encoding="UTF-8"?>
<p>New technologies for vaccine production, such as cell culture-based antigen vaccine, live attenuated influenza vaccine (LAIV), DNA vaccine, phylogenetically related seed strain vaccine, recombinant baculovirus expression vaccine, and adjuvant-containing H7-based vaccine may be serve to increase vaccination capabilities.
 <sup>
  <xref rid="bibr100-0300060519845488" ref-type="bibr">100</xref>
  <xref rid="bibr101-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr102-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr103-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr104-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr105-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr106-0300060519845488" ref-type="bibr"/>
  <xref rid="bibr107-0300060519845488" ref-type="bibr"/>–
  <xref rid="bibr108-0300060519845488" ref-type="bibr">108</xref>
 </sup> These technologies would speed up the production of H7N9 vaccines; however, a long time is likely required to produce large quantities of available vaccine. Work is ongoing in developing vaccines based on the HA and NA genes of A/Anhui/1/2013-like H7N9 viruses reassorted with the high-yield master virus A/Puerto Rico/8/34 (PR8) to enhance H7N9 virus growth capability in eggs, with high total viral and HA protein yields and attenuated pathogenesis, which has already resulted in several vaccine candidates.
 <sup>
  <xref rid="bibr29-0300060519845488" ref-type="bibr">29</xref>,
  <xref rid="bibr109-0300060519845488" ref-type="bibr">109</xref>
 </sup> LAIVs have been tested against a pandemic influenza virus.
 <sup>
  <xref rid="bibr110-0300060519845488" ref-type="bibr">110</xref>
  <xref rid="bibr111-0300060519845488" ref-type="bibr"/>–
  <xref rid="bibr112-0300060519845488" ref-type="bibr">112</xref>
 </sup>
</p>
